GAITHERSBURG, Md., May 10, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company’s first quarter ended March 31, 2016 will be released Thursday, May 12, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 4:30 p.m. E.T.  The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (international) five minutes prior to the start of the call and providing passcode 2703412.

The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at http://ir.opgen.com.   A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. 

A telephone replay also will be available from 7:30 p.m. E.T. through May 18, 2016 and may be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S.  All listeners should provide passcode 2703412. 

About OpGen
OpGen, Inc. (NASDAQ:OPGN) is developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping physicians improve patient outcomes by providing more rapid information about life threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms.  OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics.  Its QuickFISH® products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures.  Clinical laboratory services utilize the Acuitas® products, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse™ MDRO Management System designed to detect, type, track, and trend antibiotic resistant organisms in real-time.  Learn more at www.opgen.com.

Contacts:

OpGenMichael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
                           
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com